CEDRA Corporation Offers Gyrolab Instrumentation
CEDRA Corporation, a division of Worldwide Clinical Trials, announced that it has purchased the Gyrolab™ xP workstation for use in its bioanalytical research, specifically for ligand binding analysis. CEDRA is employing the new Gyrolab in its Ligand Binding Assay (LBA) laboratory in Austin, Texas.
The Gyrolab's technology changes the multistep process involved in conventional LBA applications into single procedures. The Gyrolab also has the ability to integrate assay steps for protein quantification immunoassays.
“We believe the addition of the Gyrolab to our LBA laboratories is significant and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry,” said William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation. “A key driver to our business is the dedication to staying on the forefront of technology.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
